Replied in thread
@TucsonSentinel
This could use the #medmastadon hashtag
Recent searches
Search options
Administered by:
#medmastadon
0 posts0 participants0 posts today
Know anyone who is still masking or working to avoid covid to some degree? Maybe they feel more isolated or limited socially, and having more social options that match their precautions would help.
There's a free "Covid Conscious" friends and dating match system beginning. Open to all walks of life.
It's launching in Oregon, while also offering to help anyone who wants to start their own local group anywhere else.
A community building niche for people who struggle to find others will do a lot of people some good, please spread the word.
Replied in thread
@erictopol for most of my career life-expectancy in the UK has been increasing, new medical treatments have been introduced or standard of care has improved. We are now living, in an austerity and COVID 19 era, where life expectancy is decreasing and it seems likely the prevalence of ill health will increase. Progress is not a given- a hard lesson to live #medmastadon
https://health-study.joinzoe.com/data-v3 ZOE - tracking #covid in the UK. I do not like the shape of the curve, last wave’s peak formed a nasty plateau and now on up. Certainly personally seeing a significant amount of COVID related illness and this is anecdotally the case elsewhere. Feels like a new variant, a bit out of touch with the variant tracking - tips #medmastadon ?
health-study.joinzoe.comLatest Daily UK COVID-19 Data: Vaccines, Cases, Trends | ZOECOVID infection & vaccination rates in the UK today, based on public data and reports from millions of users of the ZOE Health Study app
Replied in thread
@seachanger it’s searchable by hashtags ie #MedMastadon
This means it takes more members putting hashtags in their posts. These are also good for your bio description. I’m finding lots of good folks and posts by searching hashtags.
It’s nearly impossible to find solid info on when to get boosted and with what. If I got bivalent in September anyone have a sense of when I am ok to get a norovax booster? Is norovax still considered the right move? I have to attend a high risk work event soon (super privileged to be able to avoid such risks normally). While I will be n95 masked up, I’d love norovax to also be on my side. #covid #MedMastadon #MaskUp #CovidIsNotOver
Sending everyone warm wishes and happy holidays #selfcare #medmastadon
It’s that time of year, holidays and relaxation and family time and….MOC #medmastadon
Will we have #MedMastadon @tumorboard @tumor joining #TumorBoardTuesday this week to finish our 2022 sessions?
@quirogad & Dr Jane Meisel are joining us to discuss 2L treatment for #BRCA mutated #BreastCancer
I've been explaining to patients for years that they don't need annual lipids. Nice to have it confirmed again in this episode of my favorite podcast.
We even have some third party administrators (TPAs) that here require them of insured patients.
These are only about $20 at our office but the big hospital network here in #Maine charges over $100 for a lipid panel test. That comes out of pocket for many patients.
#medmastadon
#foamed
#costsofcare
BS Medicine-
https://therapeuticseducation.org/episode-528-proving-you-dont-need-to-repeat-cholesterol-measurements/
therapeuticseducation.org
Therapeutics Education Collaboration |
Episode 528: Proving you don’t need to repeat cholesterol measurements?
I asked ChatGPT ..."How can we fix the US healthcare system to be more efficient, equitable, and value based?" and got this in return. I think the rank ordering is telling...
New post!!
The #nhs & the unsolved challenge of stubborn tech.
A #health & social care system needs to be able to remove old & unwanted #tech to embrace newer tech.
https://priteshmistry.ghost.io/initial-insights-stubborn-tech/
Innovation in Health and Care - Pritesh MistryInitial insights: Stubborn health techIf a healthcare system like the NHS is unable to remove stubborn legacy technologies it will not get the full benefit from cutting edge technologies.
Safe private monthly coaching for residents and fellows.
Today at 6:00 pm EST
https://karapeppermd.ck.page/3c4d8418bc
Please share #medmastadon
BIG NEWS
With great pleasure I would like to share that my first book is now published and available on @amazon for purchase as a soft cover.
This is 6+ years in the making!!!
You can check it out here 
https://a.co/d/dlpZuta
Continued thread
Good morning #medtwitter and #medmastadon.
Dr Paul Farquar-Smith goes through the frankly scandalous course of the opioid crisis in America.
Corruption, misinterpretation of guidelines, fear of litigation. #WinterSymposium22
Infectious disease? More like investigative germalism #medmastadon #medicine #medschool #infection
mRNA-1273, BNT162b2, BBIBP-CorV
"Vaccine effectiveness against death related to SARS-CoV-2 infection during omicron predominance was 66.9% (6.4% to 89.8%) in children [age 3-11] and 97.6% (81.0% to 99.7%) in adolescents.
(the summary charts are misleading due to multiple axes, the tables have clearer data)
The BMJEffectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control studyObjective To estimate the effectiveness of a two dose vaccine schedule (mRNA-1273, BNT162b2, and BBIBP-CorV) against SARS-CoV-2 infection and covid-19 related death and short term waning of immunity in children (3-11 years old) and adolescents (12-17 years old) during periods of delta and omicron variant predominance in Argentina.
Design Test negative, case-control study.
Setting Database of the National Surveillance System and the Nominalized Federal Vaccination Registry of Argentina.
Participants 844 460 c hildren and adolescents without previous SARS-CoV-2 infection eligible to receive primary vaccination schedule who were tested for SARS-CoV-2 by polymerase chain reaction or rapid antigen test from September 2021 to April 2022. After matching with their corresponding controls, 139 321 (60.3%) of 231 181 cases remained for analysis.
Exposures Two dose mRNA-1273, BNT162b2, and BBIBP-CorV vaccination schedule.
Main outcome measures SARS-CoV-2 infection and covid-19 related death. Conditional logistic regression was used to estimate the odds of SARS-CoV-2 infection among two dose vaccinated and unvaccinated participants. Vaccine effectiveness was estimated as (1–odds ratio)×100%.
Results Estimated vaccine effectiveness against SARS-CoV-2 infection was 61.2% (95% confidence interval 56.4% to 65.5%) in children and 66.8% (63.9% to 69.5%) in adolescents during the delta dominant period and 15.9% (13.2% to 18.6%) and 26.0% (23.2% to 28.8%), respectively, when omicron was dominant. Vaccine effectiveness declined over time, especially during the omicron period, from 37.6% (34.2% to 40.8%) at 15-30 days after vaccination to 2.0% (1.8% to 5.6%) after ≥60 days in children and from 55.8% (52.4% to 59.0%) to 12.4% (8.6% to 16.1%) in adolescents.
Vaccine effectiveness against death related to SARS-CoV-2 infection during omicron predominance was 66.9% (6.4% to 89.8%) in children and 97.6% (81.0% to 99.7%) in adolescents.
Conclusions Vaccine effectiveness in preventing mortality remained high in children and adolescents regardless of the circulating variant. Vaccine effectiveness in preventing SARS-CoV-2 infection in the short term after vaccination was lower during omicron predominance and decreasing sharply over time.
Trial registration National Registry of Health Research IS003720.
The data that support the findings of this study will be available for researchers who provide a methodologically sound proposal after it is approved, on request from the corresponding author.
I want to switch to #MedMastadon but doing so looks so incredibly complicated I'm not sure I will.